BioSig Technologies Inc Stock Price, News & Analysis

BioSig Technologies, Inc. (NASDAQ: BSGM) announced it holds no cash or accounts at Silicon Valley Bank and has no business relationship with the bank. The company's PURE EP™ System, approved by the FDA, enhances cardiac signal visualization, making procedures more efficient. This system is being adopted by major healthcare institutions like Mayo Clinic and Cleveland Clinic. A recent study found that electrophysiologists rated the PURE EP™ System as equivalent or superior to conventional systems for 93.6% of signal samples. The global electrophysiology market is projected to reach $16 billion by 2028, growing at 11.2% annually.

BioSig Technologies (NASDAQ: BSGM) has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company's common stock price closed above $1.00 for 10 consecutive business days from February 6 to February 17, 2023. Additionally, BioSig received confirmation of compliance with the market value of listed securities, maintaining a value of $35 million or greater for 11 consecutive days from January 31 to February 17, 2023. Both compliance issues have been resolved, according to Nasdaq. BioSig's PURE EP™ System is enhancing signal visualization capabilities in electrophysiology, contributing to improved patient care.

BioSig Technologies (NASDAQ: BSGM) has announced the issuance of a new utility patent, No. 11,569,853, for its innovative PURE EP™ universal notch filtering technology. This technology enables the removal of fixed frequency interference from intracardiac signals, preserving critical data without introducing artifacts. Following this patent, the company now holds 56 worldwide patents in digital signal processing, with 11 U.S. applications pending. The PURE EP™ System is now commercially launched and shows promise in enhancing electrophysiology procedures. Recent studies indicate a high performance rating for PURE EP™ compared to conventional systems.

BioSig Technologies, Inc. (NASDAQ: BSGM) announced the retirement of CFO Steve Chaussy after 12 years, appointing Steve Buhaly as his successor. Buhaly has over 15 years of experience in public companies, including a significant role at Qorvo, contributing to its growth to an $11 billion market cap. Chaussy played a pivotal role in foundation-building for BioSig, while Buhaly's background in corporate finance and technology positions him well to support the commercial rollout of the PURE EP™ System. This transition comes as the company focuses on expanding its market presence in a projected $16 billion electrophysiology market by 2028.

BioSig Technologies, Inc. (BSGM) announced significant milestones and developments as of January 2023. The FDA 510(k)-cleared PURE EP™ System has been utilized in approximately 3,000 cases nationwide. The company is optimistic about multiple sales closings and new clinical data expected in the first half of 2023. Despite a challenging economic climate in 2022, BioSig raised $3.8 million in private placements and received an extension from Nasdaq to regain compliance with equity requirements until May 22, 2023. The global electrophysiology market is projected to reach $16 billion by 2028, indicating a promising future for BioSig's innovative technology.

BioSig Technologies (BSGM) announced that Bellin Health in Wisconsin has signed an agreement to acquire its PURE EP™ System following a successful evaluation. The system showcases significant cost savings and substantial noise reduction compared to conventional systems, enhancing procedural efficiency. With this agreement, Bellin Health gains full autonomy over the system's operation, eliminating the need for an on-site clinical account manager. BioSig's PURE EP™ technology is pivotal for advanced cardiac care, supporting better clinical decisions through superior signal visualization.

BioSig Technologies (NASDAQ: BSGM) presented promising data from its PURE EP™ System at the Asia-Pacific Heart Rhythm Society Conference. A randomized study revealed an average reduction of 11.3 minutes in procedural time during catheter ablations for patients with recurring atrial fibrillation. This translates to potential savings of approximately $418.10 per procedure, given the average operating room cost of $37 per minute. The presentation marks the first clinical data unveiling from BioSig, positioning the PURE EP™ System as a potential game-changer in healthcare efficiency.

BioSig Technologies (NASDAQ: BSGM) presented promising results from its PURE EP™ study at the Asia Pacific Heart Rhythm Society Conference in Singapore. The randomized study involving 29 patients showed that the PURE EP™ System reduced procedural times by an average of 11.3 minutes compared to traditional ECG systems, translating into potential cost savings of approximately $418.10 per procedure. This is significant given the annual performance of over 75,000 AF ablations in the US. Further studies are planned to validate these findings and explore the financial benefits for hospitals.

BioSig Technologies (NASDAQ: BSGM) announced the publication of a peer-reviewed case report on its proprietary PURE EP™ System in the Journal of Atrial Fibrillation & Electrophysiology. The report details the use of its High Frequency Algorithm (HFA) in a patient undergoing pulmonary vein isolation, demonstrating improved signal clarity and target identification for ablation therapy. Co-authored by experts from Cleveland Clinic, this study contributes to the growing clinical evidence supporting the technology. BioSig is expanding its applications through a master research agreement with Cleveland Clinic.